STA Pharmaceutical Co., a WuXi AppTec subsidiary focused on small-molecule pharmaceutical development and manufacturing, has signed a supply agreement with Tesaro, a biopharmaceutical company focused on oncology, for certain starting and intermediate materials for Tesaro’s Zejula (niraparib), used to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Under the five-year agreement, STA will provide supply of certain starting and intermediate materials for the recently launched Zejula, In March 2017, the US Food and Drug Administration (FDA) approved Zejula for epithelial ovarian, fallopian tube, or primary peritoneal cancer, and the drug is available in the US. This agreement follows a multiple-year development and clinical manufacturing arrangement between the companies that included an expedited new drug application submission and final approval by the FDA.

Source: WuXi AppTec